Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

f clinical trials, and the potential therapeutic and commercial potential, of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014  Charlene Vernak, RPh, of Vernak Farms Pharmacy ... was awarded the George Roentsch Scholarship by the Professional ... in Houston during PCCA,s International ... annually to an independent pharmacist and PCCA member who ... Roentsch , a well-known pharmacist in the compounding community. ...
(Date:10/22/2014)... DIEGO , Oct. 22, 2014 AVACEN ... medical device received 510 (k) OTC clearance by the ... AVACEN 100 to be marketed over the Internet for: ... arthritis; muscle spasms; and minor strains and sprains . ... The AVACEN 100 (MSRP $2495) is a sophisticated ...
(Date:10/22/2014)... , October 22, 2014 ... ), a clinical-stage pharmaceutical company focused on the ... positive top-line clinical results from its Phase IIa ... insulin capsules, to treat type 1 diabetes. The trial ... under a U.S. Food and Drug ...
Breaking Medicine Technology:PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
... recognized for identifying healthy solutions that empower men and women ... natural supplement which includes an ingredient that clinical tests revealed ... by 98%. Men who take Mdrive daily report ... focus. Mdrive - A synergistic blend ...
... ReportsnReports - U.S. Rehabilitation Technology Market ... This research service covers the following market ... electrotherapy - muscle Stimulators, clinical electrotherapy - ultrasound, ... diathermy, continuous passive motion (CPM) machines, clinical treatment ...
Cached Medicine Technology:DreamBrands New Formula Helps Men Feel Younger and Stronger While Naturally Raising Low-T Without Prescription Drugs 2ReportsnReports Adds Market Research Report on U.S. Rehabilitation Technology Market in its Store 2ReportsnReports Adds Market Research Report on U.S. Rehabilitation Technology Market in its Store 3ReportsnReports Adds Market Research Report on U.S. Rehabilitation Technology Market in its Store 4ReportsnReports Adds Market Research Report on U.S. Rehabilitation Technology Market in its Store 5
(Date:10/25/2014)... 2014 The global HCIT outsourcing market ... to reach $50.4 billion by 2018 from $35 billion ... and pharmaceutical industry are driving the HCIT outsourcing market. ... their focus on core business, reduce operational and maintenance ... (further reducing hiring and training costs), share risk, and ...
(Date:10/25/2014)... 25, 2014 The Wehrman ... verifies IT-accessibility for disabled users by disabled users, ... to Mackin Educational Resources of Burnsville, Minnesota, ... system and to the Minnesota Alliance for Patient ... Best Medicine" website. Both organizations have ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival in ... after his combination drug therapy became too toxic. ... posted on the Surviving Mesothelioma website. , A ... Japan suggests that “maintenance therapy” with pemetrexed may be ... tolerate higher doses of cisplatin. , “Although the ...
(Date:10/25/2014)... News) -- Researchers who discovered antibiotics in farmed ... for concern. The use of antibiotics in ... consumption contribute to the development of antibiotic-resistant bacteria ... from the study. Each year in the ... people and kill about 23,000, according to the ...
(Date:10/22/2014)... 22, 2014 At a time when ... parents and athletes at all levels, the UPMC ... the current discussion where two powerful messages are lost: ... that result in full recoveries every day. , In ... in fact and research, UPMC and the Concussion Program ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... , ... and Consultants now have an online Private Label capability to build their brand and enhance ... ... pan, Agility Consulting is introducing a new capability for Chief Learning Officers to ...
... ... Incorporated has blocked all of its ocean freight import records from the public. Meanwhile, ... to competitors and online marketers. , ... Washington D.C. (PRWEB) February 17, 2010 -- Trade Privacy LLC ...
... ... problems caused by a bad back and knees, and aggravated by arthritis. "I just can,t ... tapped into all the tools that researchers say she needs to fight the effects of ... Omaha, NE (PRWEB) ...
... , Feb. 17 The Medicare Advocacy Recovery ... Services CMS, for their decision to defer the reporting deadline ... has been working diligently to build in infrastructure to supply ... with the data share regulation." said Roy Franco , ...
... , SAN DIEGO , Feb. 17 BioMed ... promotion of Matthew G. McDevitt to the newly created ... the company,s acquisitions and leasing strategies with a focus on maximizing ... manage the execution of these strategies throughout the company,s markets. Most ...
... disease, researchers say , , WEDNESDAY, Feb. 17 (HealthDay ... less likely to develop heart disease than less happy ... prospective study of the relationship between happiness and heart ... the things that made them happy, they could significantly ...
Cached Medicine News:Health News:Agility Consulting Partners with pan (Performance Assessment Network) to Bring Custom Private Label Assessment Capability to Human Resource Professionals and Consultants 2Health News:Trade Privacy LLC: Research Concludes Apple Inc. Has Blocked Their Import Records from Public Access 2Health News:Senior Fights Frailty with Support, Attitude and Grit 2Health News:Senior Fights Frailty with Support, Attitude and Grit 3Health News:MARC Coalition Applauds Agency's Alert Regarding Delay in Data Exchange Deadline 2Health News:BioMed Realty Trust Promotes Matthew G. McDevitt to Executive Vice President, Real Estate 2Health News:BioMed Realty Trust Promotes Matthew G. McDevitt to Executive Vice President, Real Estate 3Health News:Happiness Protects Your Heart 2Health News:Happiness Protects Your Heart 3